REG - GlaxoSK Capital PLC GSK PLC - EMTN Notes repurchase results

GSKAnnouncement

13/02/2023 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230213:nRSM7801Pa&default-theme=true

RNS Number : 7801P  GlaxoSmithKline Capital PLC  13 February 2023

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIES OR
MAY QUALIFY AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7 OF THE
MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY
VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (EUWA).

GlaxoSmithKline Capital plc announces the repurchase and cancellation of
certain outstanding GBP Notes

13 February 2023

GlaxoSmithKline Capital plc (the Company) announces today that it has
purchased and cancelled the following GBP Notes issued under the Group's Euro
Medium Term Note Programme:

 

 Description of the Notes                    ISIN / Common Code       Nominal amount of GBP Notes purchased and cancelled  Aggregate Nominal Amount Outstanding after such purchase and cancellations
 5.250 per cent. Notes due 19 December 2033  XS0140516864/ 014051686  £75,783,000                                          £574,166,000
 6.375 per cent. Notes due 9 March 2039      XS0350820931/ 035082093  £68,700,000                                          £631,300,000

 

The Company

 

GlaxoSmithKline Capital plc

980 Great West Road

Brentford

Middlesex TW8 9GS

United Kingdom

 

Email: company.secretary@gsk.com

 

This announcement contains information that qualifies or may qualify as inside
information. The person responsible for arranging the release of this
announcement on behalf of GlaxoSmithKline Capital plc is Victoria Whyte,
Company Secretary.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUPWPUPWGMW